Global Painful Diabetic Neuropathy Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026

  • ID: 4564293
  • Report
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Acorda Therapeutics, Inc.
  • Eli Lilly and Company
  • Grunenthal GmbH
  • Mallinckrodt, Inc.
  • Pfizer, Inc.
  • ViroMed Co. Ltd.
  • MORE
Painful Diabetic Neuropathy Drugs Market: Growth, Future Prospects, and Competitive Analysis, 2018 -2026 the painful diabetic neuropathy drugs market was valued at US$ 4,811.8 Mn in 2017 and expected to reach US$ 8,962.0 Mn by 2026, expanding at a CAGR of 6.6 % from 2018 to 2026.

Market Insights
Global painful diabetic neuropathy drugs (PDN) market accounted to a market value of US$ 4,811.8 Mn in 2017 and projected to attain value of US$ 8,962.0 Mn by 2026 at a CAGR of 6.6% during the forecast period. The growth of this market primarily driven by the ever-growing pool of geriatric population with diabetes. The rise in availability of suitable treatment options and the growing awareness on PDN catalyzes the demand for PDN drugs. With only four drugs currently approved for the management of PDN (Lyrica, Cymbalta, Nucynta and Qutenza), there arises a huge opportunity for new and emerging market players with potential pipeline portfolio. Of the marketed products analyzed, Lyrica accounted for a maximum market share in 2017 and will continue similar trend through 2026. The recent approval of Lyrica’s control release formulation in October 2017 further augments its market growth. The PDN drugs market observes a presence of strong pipeline portfolio, which would facilitate the overall growth during the forecast period from 2018 to 2026. ViroMed Co. Ltd.’s VM202 currently in phase III is the only gene therapy developed with disease modifying properties. However, the higher pricing of gene therapy could hamper the growth of VM202 in the near future.

With diabetes being a global concern, PDN drugs market comprises a worldwide outreach. In 2017, North America dominated the market and expected to maintain its position throughout the forecast period. Availability of approved drugs and the presence of extensive diabetic patient pool contributed to the overall market growth. Asia Pacific exhibited fastest CAGR during the forecast period due to the growing awareness of PDN and the rise in healthcare expenditure.

The PDN drugs market involves partnerships and licensing agreements that boosts the overall market growth. These partnerships enable the global expansion of PDN drugs. For instance, Cymbalta, a first line PDN therapy drug originally developed by Eli Lilly & Company in collaboration with Shionogi, Inc. marketed in Japan. Other players with potential product portfolio includes Pfizer, Inc., Grunenthal GmbH, Daiichi-Sankyo Company Limited, ViroMed Co. Ltd., Collegium Pharmaceutical, Inc., Acorda Therapeutics, Inc., Zydus Pharmaceuticals USA, Inc., Mallinckrodt, Inc., and Macleods Pharmaceuticals Ltd.

Key Market Movements:
  • Globally painful diabetic neuropathy drugs market projects a steady growth with a CAGR of 6.6% during the forecast period from 2018 to 2026
  • Presence of strong product pipeline primarily contributed to the CAGR of this market
  • With only four product approved for PDN, there arises extensive opportunities for newer industrial players
  • Rising prevalence of diabetes across geographies increases the risk for PDN thus fuelling the overall market growth
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acorda Therapeutics, Inc.
  • Eli Lilly and Company
  • Grunenthal GmbH
  • Mallinckrodt, Inc.
  • Pfizer, Inc.
  • ViroMed Co. Ltd.
  • MORE
Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Market Segmentation
1.3. Research Scope
1.4. Research Methodology
1.4.1. Phase I – Secondary Research
1.4.2. Phase II – Primary Research
1.4.3. Phase III – Expert Panel Review
1.4.4. Assumptions

Chapter 2. Executive Summary
2.1. Global Painful Diabetic Neuropathy Drugs Market Portraiture
2.2. Painful Diabetic Neuropathy Drugs Market, by Drug Type, 2017 (US$ Mn)
2.3. Painful Diabetic Neuropathy Drugs Market, by Geography, 2017 (US$ Mn)

Chapter 3. Global Painful Diabetic Neuropathy Drugs Market: Dynamics and Future Outlook
3.1. Overview
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.1.1. Increased Prevalence of Diabetes
3.2.1.2. Continuous Research Activities
3.2.2. Market Challenges
3.2.2.1. Challenge 1
3.2.3. Market Opportunities
3.2.3.1. Few Approved Targeted Therapy Drugs
3.3. Attractive Investment Proposition, by Geography, 2017
3.4. Competitive Landscape, by Key Players, 2017

Chapter 4. Global Painful Diabetic Neuropathy Drugs Market, by Drug Type, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Nucynta/Palexia (Tapentadol)
4.3. Lyrica (Pregabalin)
4.4. Cymbalta (Duloxetine)
4.5. Qutenza (8% Capsaicin patch)
4.6. Tricyclic Antidepressants
4.7. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
4.8. Anticonvulsants
4.9. Opioids
4.10. Pipeline Analysis
4.10.1. Phase III Molecules (Forecast till 2026 in US$ Mn)
4.10.1.1. Mirogabalin Besylate
4.10.1.2. VM202
4.10.1.3. AmiKet
4.10.1.4. MR309
4.10.1.5. Cebranopadol
4.10.2. Phase I & Phase II Molecules (Tabular Representation)

Chapter 5. Global Painful Diabetic Neuropathy Drugs Market, by Geography, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. North America Painful Diabetic Neuropathy Drugs Market, 2016 – 2026 (US$ Mn)
5.2.1. North America Painful Diabetic Neuropathy Drugs Market, by Drug Type, 2016 – 2026 (US$ Mn)
5.2.2. North America Painful Diabetic Neuropathy Drugs Market, by Country, 2016 – 2026 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Painful Diabetic Neuropathy Drugs Market, 2016 – 2026 (US$ Mn)
5.3.1. Europe Painful Diabetic Neuropathy Drugs Market, by Drug Type, 2016 – 2026 (US$ Mn)
5.3.2. Europe Painful Diabetic Neuropathy Drugs Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Painful Diabetic Neuropathy Drugs Market, 2016 – 2026 (US$ Mn)
5.4.1. Asia Pacific Painful Diabetic Neuropathy Drugs Market, by Drug Type, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific Painful Diabetic Neuropathy Drugs Market, by Country/Region, 2016-2026 (US$ Mn)
5.4.2.1. Japan
5.4.2.2. China
5.4.2.3. Rest Of Asia Pacific
5.5. Latin America Painful Diabetic Neuropathy Drugs Market, 2016-2026 (US$ Mn)
5.5.1. Latin America Painful Diabetic Neuropathy Drugs Market, by Drug Type, 2016-2026 (US$ Mn)
5.5.2. Latin America Painful Diabetic Neuropathy Drugs Market, by Country/Region, 2016-2026 (US$ Mn)
5.5.2.1. Mexico
5.5.2.2. Brazil
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa (MEA) Painful Diabetic Neuropathy Drugs Market, 2016-2026 (US$ Mn)
5.6.1. Middle East & Africa Painful Diabetic Neuropathy Drugs Market, by Drug Type, 2016-2026 (US$ Mn)
5.6.2. Middle East & Africa Painful Diabetic Neuropathy Drugs Market, by Region, 2016-2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of Middle East & Africa

Chapter 6. Profiles
6.1. Pfizer, Inc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to Data Availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. Grunenthal GmbH
6.3. Daiichi-Sankyo Company Limited
6.4. ViroMed Co. Ltd.
6.5. Collegium Pharmaceutical, Inc.
6.6. Eli Lilly and Company
6.7. Acorda Therapeutics, Inc.
6.8. Zydus Pharmaceuticals USA, Inc.
6.9. Mallinckrodt, Inc.
6.10. Macleods Pharmaceuticals Ltd.

List of Figures
FIG. 1 Market Segmentation: Global Painful Diabetic Neuropathy Drugs Market
FIG. 2 Research Methodology: Global Painful Diabetic Neuropathy Drugs Market
FIG. 3 Global Painful Diabetic Neuropathy Drugs Market, by Drug Type, 2017 (US$ Mn)
FIG. 4 Global Painful Diabetic Neuropathy Drugs Market , by Geography, 2017 (US$ Mn)
FIG. 5 Attractive Investment Proposition, by Geography, 2017
FIG. 6 Competitive Analysis: Global Painful Diabetic Neuropathy Drugs Market, by Key Players, 2017
FIG. 7 Global Nucynta/Palexia (Tapentadol) Market for PDN, 2016-2026 (US$ Mn)
FIG. 8 Global Lyrica (Pregabalin) Market for PDN, 2016-2026 (US$ Mn)
FIG. 9 Global Cymbalta (Duloxetine) Market for PDN, 2016-2026 (US$ Mn)
FIG. 10 Global Qutenza (8% Capsaicin patch) Market for PDN, 2016-2026 (US$ Mn)
FIG. 11 Global Tricyclic Antidepressants Market for PDN, 2016-2026 (US$ Mn)
FIG. 12 Global Serotonin-Norepinephrine Reuptake Inhibitors Market for PDN, 2021-2026 (US$ Mn)
FIG. 13 Global Anticonvulsants Market for PDN, 2021-2026 (US$ Mn)
FIG. 14 Global Opioids Market for PDN, 2021-2026 (US$ Mn)
FIG. 15 Global Mirogabalin Besylate Market for PDN, 2019-2026 (US$ Mn)
FIG. 16 Global VM202 Market for PDN, 2019-2026 (US$ Mn)
FIG. 17 Global AmiKet Market for PDN, 2019-2026 (US$ Mn)
FIG. 18 Global MR309 Market for PDN, 2019-2026 (US$ Mn)
FIG. 19 Global Cebranopadol Market for PDN, 2019-2026 (US$ Mn)
FIG. 20 U.S. Painful Diabetic Neuropathy Drugs Market, 2016-2026 (US$ Mn)
FIG. 21 Canada Painful Diabetic Neuropathy Drugs Market, 2016-2026 (US$ Mn)
FIG. 22 U.K. Painful Diabetic Neuropathy Drugs Market, 2016-2026 (US$ Mn)
FIG. 23 Germany Painful Diabetic Neuropathy Drugs Market, 2016-2026 (US$ Mn)
FIG. 24 Rest of Europe Painful Diabetic Neuropathy Drugs Market, 2016-2026 (US$ Mn)
FIG. 25 Japan Painful Diabetic Neuropathy Drugs Market, 2016-2026 (US$ Mn)
FIG. 26 China Painful Diabetic Neuropathy Drugs Market, 2016-2026 (US$ Mn)
FIG. 27 Rest of Asia Pacific Painful Diabetic Neuropathy Drugs Market, 2016-2026 (US$ Mn)
FIG. 28 Mexico Painful Diabetic Neuropathy Drugs Market 2016-2026 (US$ Mn)
FIG. 29 Brazil Painful Diabetic Neuropathy Drugs Market 2016-2026 (US$ Mn)
FIG. 30 Rest of Latin America Painful Diabetic Neuropathy Drugs Market 2016-2026 (US$ Mn)
FIG. 31 GCC Painful Diabetic Neuropathy Drugs Market 2016-2026 (US$ Mn)
FIG. 32 Rest of Middle East & Africa Painful Diabetic Neuropathy Drugs Market 2016-2026 (US$ Mn)

List of Tables
TABLE 1 Global Painful Diabetic Neuropathy Drugs Market Portraiture
TABLE 2 Global Painful Diabetic Neuropathy Drugs Market, by Drug Type, 2016-2026 (US$ Mn)
TABLE 3 Global Painful Diabetic Neuropathy Drugs Market: Phase I & Phase II Pipeline Molecules
TABLE 4 Global Painful Diabetic Neuropathy Drugs Market , by Geography, 2016-2026 (US$ Mn)
TABLE 5 North America Painful Diabetic Neuropathy Drugs Market, by Drug Type, 2016-2026 (US$ Mn)
TABLE 6 North America Painful Diabetic Neuropathy Drugs Market, by Country, 2016-2026 (US$ Mn)
TABLE 7 Europe Painful Diabetic Neuropathy Drugs Market, by Drug Type, 2016-2026 (US$ Mn)
TABLE 8 Europe Painful Diabetic Neuropathy Drugs Market, by Country/Region, 2016-2026 (US$ Mn)
TABLE 9 Asia Pacific Painful Diabetic Neuropathy Drugs Market, by Drug Type, 2016-2026 (US$ Mn)
TABLE 10 Asia Pacific Painful Diabetic Neuropathy Drugs Market, by Country/Region, 2016-2026 (US$ Mn)
TABLE 11 Latin America Painful Diabetic Neuropathy Drugs Market, by Drug Type, 2016-2026 (US$ Mn)
TABLE 12 Latin America Painful Diabetic Neuropathy Drugs Market, by Country/Region, 2016-2026 (US$ Mn)
TABLE 13 Middle East And Africa Painful Diabetic Neuropathy Drugs Market, by Drug Type, 2016-2026 (US$ Mn)
TABLE 14 Middle East And Africa Painful Diabetic Neuropathy Drugs Market, by Region, 2016-2026 (US$ Mn)
TABLE 15 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16 Grunenthal GmbH: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17 Daiichi-Sankyo Company Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18 ViroMed Co. Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 Collegium Pharmaceutical, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 Eli Lilly and Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Acorda Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Zydus Pharmaceuticals USA, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Mallinckrodt, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Macleods Pharmaceuticals Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Pfizer, Inc.
  • Grunenthal GmbH
  • Daiichi-Sankyo Company Limited
  • ViroMed Co. Ltd.
  • Collegium Pharmaceutical, Inc.
  • Eli Lilly and Company
  • Acorda Therapeutics, Inc.
  • Zydus Pharmaceuticals USA, Inc.
  • Mallinckrodt, Inc.
  • Macleods Pharmaceuticals Ltd.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll